Semax vs Orexin A
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: SEMAX, Heptapeptide SEMAX
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed in Russia in the 1980s as an analog of the ACTH(4-10) fragment, with a Pro-Gly-Pro tail added to resist breakdown. It is researched and used as a neuroprotective and nootropic agent, typically intranasally, and keeps the cognitive and neurotrophic effects of the ACTH fragment without the parent hormone's cortisol-raising activity. It is used clinically and registered in Russia (including for ischemic stroke and cognitive disorders) but is not approved by the FDA or EMA, and Western evidence is limited.
Also: Hypocretin-1, Hcrt-1
Orexin A (also called hypocretin-1) is a 33-amino-acid brain peptide made by a small cluster of neurons in the hypothalamus, and it is one of the main signals that keeps you awake. People with narcolepsy type 1 have lost most of these neurons, and orexin is undetectable in their spinal fluid. Orexin A itself is not an approved drug, but a few small German studies have sprayed it into the nose of narcolepsy patients and healthy men with measurable effects. Interesting science, very early stage.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Semax | Orexin A |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Semax is derived from ACTH(4-10) but, unlike ACTH, does not stimulate the adrenal or cortisol axis; its main documented action is upregulating brain-derived neurotrophic factor (BDNF) and its receptor TrkB, especially in the hippocampus. In rats, a single dose increases BDNF protein and mRNA and raises TrkB phosphorylation, activating growth and survival pathways (such as MAPK/ERK and PI3K/Akt) that support neuron health and plasticity. It also modulates dopamine and serotonin signaling and influences genes tied to the immune and vascular response after brain ischemia. The combined effect in animal models is neuroprotection against insults like reduced blood flow and oxidative stress, plus enhanced learning and memory. The Pro-Gly-Pro extension makes it more stable than the bare ACTH(4-10) sequence, which is partly why it stays active intranasally. | Orexin A activates both orexin receptors (OX1R and OX2R) with high affinity. Those receptors sit on brainstem and hypothalamic arousal centers (the histamine, noradrenaline, dopamine and acetylcholine systems), so orexin acts like a stabilizer that keeps the brain locked in the wake state and stops it slipping into REM sleep at the wrong time. Losing it causes narcolepsy: orexin knockout mice and dogs with a broken OX2R gene both develop narcolepsy, and giving orexin A into the brain of narcoleptic mice suppressed cataplexy. Orexin also drives appetite and raises sympathetic nerve activity. A mouse study found orexin A crosses the blood-brain barrier fairly well, and the nasal route is used in humans to deliver more of it to the brain. |
| Common Dosing | 200-600 mcg daily 1-3x daily | 435 nmol (about 1.5 mg) intranasal Single dose in studies |
| Administration | Intranasal spray (most common) | Intranasal spray |
| Typical Duration | 10-30 days typical | Single doses only in published human studies |
| Best Time to Take | Morning or early afternoon | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The mechanistic core is well documented preclinically: Dolotov et al. (2006, Brain Research) showed a single intranasal Semax dose raised hippocampal BDNF protein, TrkB phosphorylation, and BDNF and TrkB mRNA in rats, alongside improved learned behavior. Additional rat work shows neuroprotection and changes in immune- and vascular-related gene expression after experimental stroke. Human clinical use is real but the published trials are mostly Russian-language, small, and frequently non-randomized or open-label: studies in acute ischemic-stroke patients reported faster recovery of neurological function, and a 2018 study reported increased plasma BDNF with improvements on disability and motor scales. These results are promising but methodologically weaker than Western regulatory-grade trials and have not been replicated in large independent Western studies. Honest summary: solid animal mechanistic data and decades of Russian clinical use, but the human cognitive and stroke claims rest on small, mostly non-randomized studies and are not validated by FDA or EMA-grade trials. | The human data comes from a handful of small, placebo-controlled crossover studies, mostly from one group in Kiel, Germany. In 2008, intranasal orexin A improved smell detection thresholds in 7 narcolepsy patients. In 2011, a single 435 nmol nasal dose before bed in 8 patients did not change nighttime wakefulness but reduced REM sleep and wake-to-REM transitions. In 2014, the same dose given in the morning to 14 patients reduced wake-REM transitions and improved divided attention (fewer errors). In 2022, 500 nmol in 10 healthy men acutely raised sympathetic nerve activity to blood vessels, without changing blood pressure or heart rate. In sleep-deprived monkeys, nasal orexin A reversed some of the drop in memory performance (Deadwyler, 2007). That is the whole human record: single doses, tiny groups, short-term outcomes. The real clinical action has moved to small-molecule drugs that mimic orexin at OX2R. Takeda's oveporexton (brand name Orzeyful) was FDA-approved on August 5, 2026 for narcolepsy type 1, which validates the target but is not the same thing as using the peptide. |
Frequently Asked Questions: Semax vs Orexin A
What is the difference between Semax and Orexin A?
Semax is a cognitive peptide that semax is a synthetic heptapeptide (met-glu-his-phe-pro-gly-pro) developed in russia in the 1980s as an analog of the acth(4-10) fragment, with a pro-gly-pro tail added to resist breakdown. it is researched and used as a neuroprotective and nootropic agent, typically intranasally, and keeps the cognitive and neurotrophic effects of the acth fragment without the parent hormone's cortisol-raising activity. it is used clinically and registered in russia (including for ischemic stroke and cognitive disorders) but is not approved by the fda or ema, and western evidence is limited. Orexin A is a cognitive peptide that orexin a (also called hypocretin-1) is a 33-amino-acid brain peptide made by a small cluster of neurons in the hypothalamus, and it is one of the main signals that keeps you awake. people with narcolepsy type 1 have lost most of these neurons, and orexin is undetectable in their spinal fluid. orexin a itself is not an approved drug, but a few small german studies have sprayed it into the nose of narcolepsy patients and healthy men with measurable effects. interesting science, very early stage. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Semax or Orexin A?
Neither is universally "better" - the choice depends on your specific goals. Semax is typically used for cognitive purposes, while Orexin A is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Semax and Orexin A be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Semax and Orexin A together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.